Skip to content
10-Q

Quarterly Report

Syndax Pharmaceuticals, Inc. SNDX

0001193125-26-197154

← back to feed
Filed
Apr 30, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 27, 2026 88.61M sh
Shares Diluted Q1 2026 · Mar 31, 2026 88.26M sh
Shares Diluted Q1 2026 · Mar 31, 2025 86.17M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$50.35M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$95.16M
Short Term Debt Q1 2026 · Mar 31, 2026 $343.97M
Short Term Debt Q1 2026 · Dec 31, 2025 $343.91M
Short Term Investments Q1 2026 · Mar 31, 2026 $221.17M
Short Term Investments Q1 2026 · Dec 31, 2025 $259.14M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $130.89M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $134.93M
Stockholders Equity Q1 2026 · Mar 31, 2026 $41.62M
Stockholders Equity Q1 2026 · Dec 31, 2025 $64.63M
Stockholders Equity Q1 2026 · Mar 31, 2025 $215.06M
Stockholders Equity Q1 2026 · Dec 31, 2024 $288.12M
Current Liabilities Q1 2026 · Mar 31, 2026 $86.17M
Current Liabilities Q1 2026 · Dec 31, 2025 $120.12M
Total Liabilities Q1 2026 · Mar 31, 2026 $431.05M
Total Liabilities Q1 2026 · Dec 31, 2025 $465.08M
Current Assets Q1 2026 · Mar 31, 2026 $471.18M
Current Assets Q1 2026 · Dec 31, 2025 $528.08M
Total Assets Q1 2026 · Mar 31, 2026 $472.67M
Total Assets Q1 2026 · Dec 31, 2025 $529.71M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.48
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.98
Eps Basic Q1 2026 · Mar 31, 2026 −$0.48
Eps Basic Q1 2026 · Mar 31, 2025 −$0.98
Rd Expense Q1 2026 · Mar 31, 2026 $58.85M
Rd Expense Q1 2026 · Mar 31, 2025 $61.64M
Net Income Q1 2026 · Mar 31, 2026 −$42.67M
Net Income Q1 2026 · Mar 31, 2025 −$84.85M
Operating Income Q1 2026 · Mar 31, 2026 −$34.2M
Operating Income Q1 2026 · Mar 31, 2025 −$83.76M
Revenue Q1 2026 · Mar 31, 2026 $64.86M
Revenue Q1 2026 · Mar 31, 2025 $20.04M